Compare OSS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | IKT |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.4M | 181.9M |
| IPO Year | 2018 | 2020 |
| Metric | OSS | IKT |
|---|---|---|
| Price | $7.55 | $1.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $8.50 | $4.00 |
| AVG Volume (30 Days) | ★ 684.2K | 411.5K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,264,017.00 | N/A |
| Revenue This Year | $18.00 | N/A |
| Revenue Next Year | $9.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.33 | N/A |
| 52 Week Low | $1.85 | $1.33 |
| 52 Week High | $7.92 | $4.20 |
| Indicator | OSS | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 70.78 | 53.05 |
| Support Level | $5.81 | $1.43 |
| Resistance Level | $7.92 | $1.57 |
| Average True Range (ATR) | 0.53 | 0.10 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 90.17 | 73.81 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.